Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865163 | 0.91 | SMO (0.56) | SMOALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL4873337 | 0.76 | MAPT (0.51) | SMOALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL4872133 | 0.76 | CNR1 (0.44) | ALDH1A1HPGDSMN1; SMN2MAPTGAA | |
| SCHEMBL4869555 | 0.75 | NAMPT (0.43) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4868670 | 0.74 | JAK2 (0.55) | ALDH1A1HPGDSMN1; SMN2MAPTTP53 | |
| SCHEMBL4869419 | 0.74 | MAPT (0.60) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4865624 | 0.74 | PTGES (0.49) | ALDH1A1HPGDSMN1; SMN2MAPTTP53 | |
| SCHEMBL4260914 | 0.71 | SMO (1.00) | SMOALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL4873827 | 0.71 | MAPT (0.61) | SMOALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL4871581 | 0.70 | MAPT (0.43) | SMOALDH1A1HPGDSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326790-B2 | Diphenylisoxazole compounds and hydro isomers thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7220745-B2 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1641452-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | Rigel Pharmaceuticals (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1620412-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | MIDCAP FINANCIAL TRUST | 2004-12-16 | — | — | US | disclosed |
| WO-2004103366-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | RIGEL PHARMACEUTICALS (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004099165-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | HAVCR2, PCNA, HCCS | SMO 2235/4885ALDH1A1 1236/4885HPGD 712/4885 |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | HAVCR2, PCNA, HCCS | SMO 1283/4885ALDH1A1 491/4885HPGD 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.